anastrozole has been researched along with Osteoporosis in 21 studies
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer." | 9.19 | Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. ( Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B, 2014) |
| "In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole." | 9.17 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013) |
| "6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer." | 9.13 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer." | 5.19 | Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. ( Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B, 2014) |
| "In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole." | 5.17 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013) |
| "6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer." | 5.13 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion." | 4.81 | [Antiestrogen therapy in the treatment of breast neoplasms]. ( Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G, 2002) |
| "Combined therapy with BJD and alendronate can act synergistically against osteoporosis, which was possibly related to a reduced bone conversion rate through inhibiting bone resorption." | 3.85 | Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. ( Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ, 2017) |
| "Aromatase inhibitors like anastrozole play an undisputed key role in the treatment of breast cancer, but on the other hand, various side effects like osteoporosis and increased risk of bone fracture accompany the chronic administration of these drugs." | 3.79 | Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats. ( Kaur, J; Tikoo, K; Vekariya, KK, 2013) |
| "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels." | 2.46 | Women and bone health: maximizing the benefits of aromatase inhibitor therapy. ( Tang, SC, 2010) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | 1.35 | Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008) |
| "Subjects were 17 postmenopausal breast cancer patients (mean age, 63." | 1.34 | Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. ( Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, AA | 1 |
| Ahmed, MM | 1 |
| Gomaa, M | 1 |
| Ebraheim, LLM | 1 |
| Vekariya, KK | 1 |
| Kaur, J | 1 |
| Tikoo, K | 1 |
| Beck, DT | 1 |
| Yarrow, JF | 1 |
| Beggs, LA | 1 |
| Otzel, DM | 1 |
| Ye, F | 1 |
| Conover, CF | 1 |
| Miller, JR | 1 |
| Balaez, A | 1 |
| Combs, SM | 1 |
| Leeper, AM | 1 |
| Williams, AA | 1 |
| Lachacz, SA | 1 |
| Zheng, N | 1 |
| Wronski, TJ | 1 |
| Borst, SE | 1 |
| Liu, P | 1 |
| Yang, DQ | 1 |
| Xie, F | 1 |
| Zhou, B | 1 |
| Liu, M | 2 |
| Goss, PE | 2 |
| Ingle, JN | 2 |
| Kubo, M | 1 |
| Furukawa, Y | 1 |
| Batzler, A | 1 |
| Jenkins, GD | 1 |
| Carlson, EE | 1 |
| Nakamura, Y | 1 |
| Schaid, DJ | 1 |
| Chapman, JA | 2 |
| Shepherd, LE | 2 |
| Ellis, MJ | 2 |
| Khosla, S | 1 |
| Wang, L | 1 |
| Weinshilboum, RM | 1 |
| Sestak, I | 1 |
| Singh, S | 1 |
| Cuzick, J | 1 |
| Blake, GM | 1 |
| Patel, R | 1 |
| Gossiel, F | 1 |
| Coleman, R | 1 |
| Dowsett, M | 1 |
| Forbes, JF | 1 |
| Howell, A | 1 |
| Eastell, R | 1 |
| Huang, XH | 1 |
| Liang, RH | 1 |
| Su, L | 1 |
| Guo, W | 1 |
| Wang, CJ | 1 |
| Khachidze, N | 1 |
| Giorgadze, E | 1 |
| Tsagareli, M | 1 |
| Gnant, M | 1 |
| Mlineritsch, B | 1 |
| Luschin-Ebengreuth, G | 1 |
| Kainberger, F | 1 |
| Kässmann, H | 1 |
| Piswanger-Sölkner, JC | 1 |
| Seifert, M | 1 |
| Ploner, F | 1 |
| Menzel, C | 1 |
| Dubsky, P | 1 |
| Fitzal, F | 1 |
| Bjelic-Radisic, V | 1 |
| Steger, G | 1 |
| Greil, R | 1 |
| Marth, C | 1 |
| Kubista, E | 1 |
| Samonigg, H | 1 |
| Wohlmuth, P | 1 |
| Mittlböck, M | 1 |
| Jakesz, R | 1 |
| Gibson, K | 1 |
| O'Bryant, CL | 1 |
| Gheita, TA | 1 |
| Ezzat, Y | 1 |
| Sayed, S | 1 |
| El-Mardenly, G | 1 |
| Hammam, W | 1 |
| Markopoulos, C | 2 |
| Tang, SC | 1 |
| Tzoracoleftherakis, E | 1 |
| Koukouras, D | 1 |
| Venizelos, B | 1 |
| Zobolas, V | 1 |
| Misitzis, J | 1 |
| Xepapadakis, G | 1 |
| Gogas, H | 1 |
| Pritchard, KI | 1 |
| Sledge, GW | 1 |
| Budd, GT | 1 |
| Rabaglio, M | 1 |
| Ansari, RH | 1 |
| Johnson, DB | 1 |
| Tozer, R | 1 |
| D'Souza, DP | 1 |
| Chalchal, H | 1 |
| Spadafora, S | 1 |
| Stearns, V | 1 |
| Perez, EA | 2 |
| Liedke, PE | 1 |
| Lang, I | 1 |
| Elliott, C | 1 |
| Gelmon, KA | 1 |
| Coleman, RE | 1 |
| Aumiller, J | 1 |
| Gralow, JR | 1 |
| Yonehara, Y | 1 |
| Iwamoto, I | 1 |
| Kosha, S | 1 |
| Rai, Y | 1 |
| Sagara, Y | 1 |
| Douchi, T | 1 |
| Alba, E | 1 |
| Ragonesi, G | 1 |
| Colla, F | 1 |
| Mazzoleni, A | 1 |
| Farina, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenetics of Aromatase Inhibitors[NCT00283608] | 1,000 participants (Anticipated) | Observational | 2005-07-31 | Completed | |||
| International Breast Cancer Intervention Study[NCT00078832] | Phase 3 | 3,864 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study[NCT03401619] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2017-09-21 | Active, not recruiting | |||
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)[NCT00295646] | Phase 3 | 1,803 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
| A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573] | Phase 3 | 7,576 participants (Actual) | Interventional | 2003-06-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 358 |
| Anastrozole | 354 |
Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 157 |
| Anastrozole | 164 |
Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Exemestane | 88 |
| Anastrozole | 89 |
Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Exemestane | 92 |
| Anastrozole | 92 |
5 reviews available for anastrozole and Osteoporosis
| Article | Year |
|---|---|
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adj | 2017 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Che | 2003 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
5 trials available for anastrozole and Osteoporosis
| Article | Year |
|---|---|
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Ar | 2014 |
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Fem | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidr | 2014 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Fe | 2013 |
11 other studies available for anastrozole and Osteoporosis
| Article | Year |
|---|---|
Bone health consequence of adjuvant Anastrozole in monotherapy or associated with biochanin-A in ovariectomized rat model.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Animals; Female; Genistein; Osteoporosis; Ovariectomy; Phytoes | 2018 |
Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.
Topics: Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone and Bones; Cells, Cultured; F | 2013 |
Influence of aromatase inhibition on the bone-protective effects of testosterone.
Topics: Anabolic Agents; Anastrozole; Androgens; Animals; Aromatase; Aromatase Inhibitors; Heptanoates; Male | 2014 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2010 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clini | 2005 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromata | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |